{"filing":{"accession_number":"0001193125-26-306737","cik":"0001754068","ticker":"KLRS","company_name":"Kalaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-17","report_date":null,"primary_document":"d125006d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm"},"events":[{"id":18571,"run_id":16696,"accession_number":"0001193125-26-306737","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kalaris disclosed positive Phase 1a clinical trial data for its lead candidate TH103 in neovascular AMD, including expanded cohort results (17 treatment-naïve, 3 treatment-experienced patients) showing improvements in vision (9.2-letter BCVA improvement), retinal anatomy (118µm OCT improvement), extended time-to-retreatment, and favorable pharmacokinetic findings with extended intraocular retention and improved safety profile.","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-17","form":"8-K","submitted_at":null,"items":[{"id":17416,"accession_number":"0001193125-26-306737","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kalaris disclosed positive Phase 1a clinical trial data for its lead candidate TH103 in neovascular AMD, including expanded cohort results showing improvements in vision, retinal anatomy, and extended time-to-retreatment. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. The disclosure is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:06:43.097057+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17417,"accession_number":"0001193125-26-306737","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kalaris disclosed positive clinical trial data from its Phase 1a SAD trial of TH103 in neovascular AMD, including expanded patient cohorts (17 treatment-naïve, 3 treatment-experienced patients), efficacy improvements (9.2-letter BCVA improvement, 118µm OCT improvement), and pharmacokinetic findings showing extended intraocular retention. While this is clinical-stage progress rather than a discrete operational event like a partnership or regulatory milestone, it represents material advancement of the company's lead therapeutic candidate that would affect investor assessment of development trajectory and commercial potential. The disclosure emphasizes data consistency, safety profile improvements (no IOI cases at 2.5 mg dose), and ongoing Phase 1b/2 enrollment with results expected in 1H 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:06:43.097057+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17416,"accession_number":"0001193125-26-306737","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kalaris disclosed positive Phase 1a clinical trial data for its lead candidate TH103 in neovascular AMD, including expanded cohort results showing improvements in vision, retinal anatomy, and extended time-to-retreatment. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. The disclosure is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:06:43.097057+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-17"},{"id":17417,"accession_number":"0001193125-26-306737","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kalaris disclosed positive clinical trial data from its Phase 1a SAD trial of TH103 in neovascular AMD, including expanded patient cohorts (17 treatment-naïve, 3 treatment-experienced patients), efficacy improvements (9.2-letter BCVA improvement, 118µm OCT improvement), and pharmacokinetic findings showing extended intraocular retention. While this is clinical-stage progress rather than a discrete operational event like a partnership or regulatory milestone, it represents material advancement of the company's lead therapeutic candidate that would affect investor assessment of development trajectory and commercial potential. The disclosure emphasizes data consistency, safety profile improvements (no IOI cases at 2.5 mg dose), and ongoing Phase 1b/2 enrollment with results expected in 1H 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:06:43.097057+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-17"}]}